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Background: Detecting among patients with aortic stenosis (AS) those who are likely
to rapidly progress, yet potentially benefiting from prophylactic aortic valve replacement,
is needed for improved patient care. The objective of this study was to evaluate the role
of imaging biomarkers in predicting the progression to clinical symptoms and death in
patients with AS.
Methods: We searched the Pubmed and the International Clinical Trials Registry
Platform databases for studies including patients with AS, and investigating imaging
techniques, published in any language until Jan 1, 2018. Eligible sets of data include
effect of imaging biomarkers relative to: (1) Overall mortality, (2) Cardiac mortality,
and (3) Overall events (Symptom onset and Major Adverse Cardiovascular Events).
Meta-analysis was used to examine associations between the imaging biomarkers and
outcomes of AS using Random Effect models.
Results: Eight studies and 1,639 patients were included after systematic review. Four
studies investigated aortic valve calcification (AVC) whereas the remaining investigated
biomarkers provided by cardiac magnetic resonance (CMR). Four articles investigated
the presence of midwall fibrosis on late-gadolinium enhancement imaging, three reported
its extent (LGE%) and two, the myocardial extracellular volume (ECV). By decreasing
strength of association, there were significant associations between cardiac mortality
and LGE% [Relative Risk (RR) = 1.05, 95% Confidence Interval (CI) 1.01–1.10];
overall mortality and AVC (RR = 1.19, 95%CI: 1.05–1.36); overall events and ECV
(RR = 1.68, 95%CI: 1.17–2.41); cardiac mortality and midwall fibrosis (RR = 2.88,
95%CI: 1.12–7.39).
Conclusion: AVC and myocardial fibrosis imaging biomarkers predict the outcomes in
AS, and help understanding AS pathophysiology and setting therapeutic targets.
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INTRODUCTION
Degenerative aortic stenosis (AS) is one of the most common
valvular diseases, affecting up to 6% of subjects over 75 years
old in developed countries (1). AS progresses with time in such
a way that the only effective treatment is surgical or transcatheter
aortic valve replacement (AVR). In the recent years, it has been
growingly acknowledged that AS encompasses a wide spectrum
of pathways in response to the progressive obstruction of the left
ventricular (LV) outflow. These include first adaptive responses
such as LV concentric hypertrophy that relieves the wall stress
in response to LV overload, then maladaptive responses such
as myocardial ischemia and fibrosis that eventually lead to
myocardial dysfunction and cardiac output failure (2, 3). The
concurrent progresses in computed tomography (CT), cardiac
magnetic resonance imaging (CMR) and positron emission
tomography (PET) have given rise to imaging biomarkers
allowing quantification of the structural remodeling of both the
aortic valve and the underlying myocardium (4). On a clinical
view, the current indications for AVR are severe AS (peak
aortic jet velocity ≥4 m/s, mean transvalvular pressure gradient
≥40mm Hg, aortic valve area (AVA) ≤1.0 cm2 or ≤0.6 cm2/m2)
causing clinical symptoms, or a decreased LV ejection fraction
(<50%) (5, 6). Nevertheless, intervening too late in the disease
course (i.e., when adverse remodeling and fibrosis processes
have become irreversible) is associated with poor post-operative
outcomes (7). Even with severe AS, the symptomsmay be difficult
to unmask in aged patients, as almost one half report no symptom
at the time of diagnosis (8). There is therefore a need to detect
from clinical, biological, and imaging tests, patients with AS
who are likely to rapidly progress to symptoms, yet potentially
benefiting from AVR. Several imaging biomarkers have been or
are currently being considered at different levels of evidence to
stratify the risk in asymptomatic severe AS. The objective of
this study was to determine which imaging biomarkers (derived
from CT and CMR) were associated with the prediction of AS
progression to clinical symptoms and death.
METHODS
We carried out a systematic review in accordance with
the PRISMA guidelines, following a protocol in accordance
with the PRISMA-P statement (9). The online free database
Medline (via PubMed) was searched for eligible articles.
The date of the last search was January 1, 2018. The
International Clinical Trials Registry Platform was searched
for ongoing studies. The literature search was performed
with assistance from an experienced librarian. The search
strategy combined four sets of search terms (keywords), in
accordance with the “Patient-Intervention-Control-Outcome”
methodology. The first set of keywords defined AS (i.e.:
aortic valve stenosis. . . ), the second defined imaging techniques
(i.e.: Computed Tomography, Electron-Beam Tomography,
Magnetic Resonance Imaging, Positron Emission Tomography
. . . ), the third defined remodeling processes (i.e.: calcification,
hypertrophy, fibrosis, ischemia. . . ), and the fourth defined
the clinical outcomes [i.e.: death, mortality, cardiovascular
events (decompensation, edema, angina), progression, onset,
survival. . . ]. All keyword searches were combined to subject
heading searches when appropriate. The full search strategy is
provided in the Supplementary Table 1. Only original papers,
clinical trials and studies, controlled and observational trials, with
available full-text in English were included. Studies were eligible
if they included only adult patients with AS, and investigated at
least one diagnostic imaging technique focusing on the calcific
remodeling of the valve, myocardial microvascular obstruction,
myocardial fibrosis. Studies that did not relate the imaging results
to AS progression ormortality were not included. Reports of pilot
studies describing fewer than five patients were excluded.
Data Extraction
Two reviewers with experience in cardiovascular imaging
assessed in consensus all titles and abstracts for relevance
and eligibility. The full text of potentially relevant articles
was retrieved. If full text articles were not available, the
corresponding authors were contacted. Reference lists from
included articles were searched for other relevant articles. The
reviewers extracted and processed the data in standardized
extraction forms. Corresponding authors were contacted for
additional information if data were unclear or incomplete.
Items included the last name of the first author and year of
publication, study design, objective, sample size, inclusion, and
exclusion criteria, patient characteristics, AS grade, follow-up
period, funding source, technical aspects of imaging modalities,
methods of measurement, interpretation of imaging results, and
quantitative imaging results, measure of effect sizes [as relative
risk (RR)].
Risk of Bias Assessment
Study quality and risk of bias was assessed using Cochrane
Collaboration’s tool for assessing risk of bias (10). Ten specific
bias domains were used in the form of answering pre-specified
questions about the methods reported by each study in relation
to the risk domain, such that the conclusion is either “no” (“–”,
indicating high risk of bias), “not reported” (“NR”, indicating
unclear risk of bias), or “yes” (“+”, indicating low risk of bias).
Statistical Analysis
Three outcomes of AS were considered for this review: (1)
Overall mortality, (2) Cardiac mortality, and (3) Overall events
[Symptom onset and Major Adverse Cardiovascular Events
(MACE)]. Meta-analyses were done using the metagen function
from the R package meta (11, 12). For each study considered,
measures of effect were represented as RR and its corresponding
95% CIs. Conversion of effect sizes were done using the
approach of Borenstein et al. (13) where RRs were not reported
directly. Biomarkers with more than one effect measures in a
study were combined using fixed effect model. The strength
of association of each biomarker with the outcomes were
quantified by pooling the RRs provided by the original studies
using either Fixed or Random effect models and the results
are represented as forest plots. Statistical heterogeneity between
studies was assessed using the I² and Tau². To investigate
publication bias, funnel plots were produced in addition to the
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use of Egger’s regression test. In order to rank biomarkers with
respect to effects on outcomes, the average RRs and measures
of variability were converted to odds ratios (ORs) using the
formula at the Supplementary Information 1. These ORs were
later on transformed to Hedges’ g, a common index of effect
size, as stated elsewhere (13). With the use of the normal-
normal hierarchical model (NNHM), a Bayesian random effect
model was implemented using the bayesmeta package in R for
evaluating the strength of association for each biomarker with
the outcome. A normal prior was used for the overall mean
whereas a half student-t was used as prior for the measure
of heterogeneity among the effect sizes of each biomarker.
Posterior predictive P-values (PPPV) were computed using 1,000
Monte Carlo sampling. Then, sensitivity analysis for ranking of
biomarker effects was done by fitting a consistency random effect
network meta-analysis (NMA) assuming a common reference
group for each biomarker effect. Hedges’ g was computed for
each study separately before being combined in the NMA
(Supplementary Figure 1). The appropriate NMA model was
conducted in OpenBugs using 2 chains with different starting
values and a burn-in of 50 k after 500 k iterations. Convergence
of the model was assessed using history and density plots
FIGURE 1 | PRISMA flowchart of study selection.
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(Supplementary Figures 3, 4). For each Marcov Chain Monte
Carlo (MCMC) run, each biomarker is ranked using the absolute
value of the Hedges’ g. Probabilities of being the first, second and
up till the last are estimated and represented on a Cumulative
probability plot. These probabilities are used to estimate the
surface under the cumulative rank (SUCRA) curve which
determined the strength of the biomarker with the outcome. All
analyses were done using R studio (R version 3.4.2) and a p-value
of <5% was considered statistically significant.
RESULTS
The search strategy identified 540 citations (Figure 1). After
screening of titles and abstracts, twenty articles were selected
for full-text review. After full-text review, one study was
excluded because it didn’t report the patient status regarding
AS upon inclusion (14). Seven studies were excluded because
they used different endpoints than clinical outcome to investigate
imaging results, or mixed (clinical and imaging) data to
determine the outcome of AS (15–21). One other study (22)
was excluded because it briefly reported the 5-year follow-
up of a cohort assessed previously by Dweck et al. (23). Five
studies were excluded as they report the outcomes of patients
regarding imaging results, after AVR (24–28). One study was
excluded because it was retrospective and evaluated only a
subset of patients with low-gradient and low-flow (29). Three
additional studies were found through cross-referencing (30–
32). Subsequently, eight articles were included in this systematic
review (Supplementary Table 2). All included studies were
prospective and their sample sizes ranged from 34 to 794 patients,
with a total number of 1,639 patients in this review.
The patient and AS characteristics are summarized in
Table 1. Four articles investigated aortic valve calcification (AVC)
with electron-beam CT (EBCT) (33) and conventional photon
multislice CT (MSCT) (30, 31, 34). Four studies investigated
LV myocardial fibrosis using late-gadolinium-enhancement
(LGE) CMR; all investigating midwall replacement fibrosis (23,
32, 35, 36). Three of these studies investigated replacement
fibrosis quantification (LGE%) (32, 35, 36), and two studies
evaluated interstitial fibrosis via the extracellular volume (ECV)
measurement (35, 36). Lastly, single CMR studies investigated
respectively the myocardial perfusion reserve (MPR) as a
marker of microvascular dysfunction in AS (36), and native
(unenhanced) T1 value as a marker of myocardial fibrosis
(32). Included articles reported patient cohorts from Europe,
United Kingdom, USA, Canada and South Korea. The overall
findings of the risk of bias assessment were: a low risk of selection
attrition and outcome reporting bias, and varied risk of detection
and commercial bias as the outcome adjudication blinding was
nearly systematically unreported, and some investigators related
to the industry in four studies (23, 32, 35, 36). All the studies
recorded are of moderate-to-low risk of bias with overall quality
of 50% or more (Supplementary Table 3).
Meta-analyses were restricted to the biomarkers that were
reported in at least 2 studies. As listed in Table 2, there were
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TABLE 2 | Associations between imaging biomarkers, effect size (Variability), and outcomes in AS.
References Imaging
method
Biomarker Outcome RR Measure of














Feuchtner et al. (30) MSCT AVC MACE 3.18 1.64 1.16 0.49















Utsunomiya, et al. (31) MSCT AVC OE 1.09 1.04–1.15 0.09 0.03


























































AVC, aortic valve calcification; EBCT, electron-beam computed tomography; MSCT, multisclice computed tomography; LGE, late-gadolinium enhancement; ECV, extracellular volume;
MACE, major adverse clinical event; OM, overall mortality; OE, overall events; LE, late events; CM, cardiac mortality; ASE, aortic stenosis related-event; CI, confidence interval; RR,
relative risk; SE, standard error; Ln, neperian logarithm.
for a biomarker was pooled into one using fixed effect model.
The primary outcome was all-cause mortality in three studies
(23, 34, 35), and a softer endpoint including cardiac- or AS-
related mortality, MACE, AS-related symptoms or AVR in the
remaining. Results from the meta-analyses confirmed significant
associations between AVC and Overall mortality (RR = 1.19,
95%CI: 1.05–1.36); Midwall Fibrosis and Cardiac mortality
(RR = 2.88, 95%CI: 1.12–7.39), LGE percent and Cardiac
mortality (RR = 1.05, 95%CI: 1.01–1.10); ECV and Overall
events (RR = 1.68, 95%CI: 1.17–2.41) (Figure 2). For all the
biomarkers, higher values are associated with higher risks of
having outcomes of AS, but substantial inconsistency of effect
was observed for AVC, and midwall fibrosis with both I2 >75%.
Because of the limited number of studies, assessment of and
further correction for bias could not be sufficiently ascertained.
Ranking of biomarkers in order of decreasing strength of
association with the outcomes resulted in LGE% (PPPV<0.0001)
being at the top and midwall fibrosis (PPPV = 0.456) at the
bottom (Table 3). Similar rankings were observed using the
SUCRA values from the NMA (Supplementary Figure 2).
DISCUSSION
This systematic review and meta-analysis showed significant
associations between imaging biomarkers of aortic valve
remodeling and myocardial fibrosis and clinical outcomes in
patients with AS. Five years after receiving the diagnosis,
approximately two-thirds of conservatively managed patients
with asymptomatic AS will develop symptoms, and 75% will have
either died or undergone AVR (37). During this time period, it is
questionable in how far they would not exhibit raised biomarkers
of poor outcome before developing clinical symptoms, altered
hemodynamic or performance status. Imaging biomarkers with
prognostic value in AS are often correlated with hemodynamic
and clinical performance. The aortic valve calcium (AVC) score
for instance is recommended in the management of patients with
AS, not as a prognostic factor, but to determine the likelihood of
severe AS in case of low-gradient, low-flow and preserved LVEF
(6), due to its association to AS severity (16, 34). The findings
of our analysis advocates for an additional prognostic use this
score, as all four articles investigating AVC reported association
with mortality; with an overall RR of 1.19, 95%CI: 1.05–1.36)
(30, 31, 33, 34). Even though only the largest among these studies
(34) introducedAVCdensity to compensate for differences in aortic
annular area, there were little measurement bias, as a highly
reproducible and standardized score was systematically reported
(16, 17, 38).
Similar risk stratification to AVC is expected from non-
invasively assessed LV myocardial fibrosis, a fourfold potential
courtesy of CMR using the effects of gadolinium-based contrast
agents. These agents strongly decrease the T1 relaxation time of
the tissues. As such, they can be used for track-bolus kinetics
within the myocardium and assess resting and stress perfusion,
thus MPR, which is potentially a marker of microvascular
dysfunction (36). Gadolinium-based contrast agents distribute
in the plasma and extracellular spaces, which means they do
not enter normal cells. Upon equilibrium distribution (i.e.,
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FIGURE 2 | Forest plots showing the average relative risks for the strength of association between imaging biomarkers and outcomes in AS. AVC, aortic valve
calcification; LGE, late gadolinium enhancement; ECV, extracellular volume. (A) (AVC: I2 = 87.1, Tau2 = 0.01, n = 992). (B) (Midwall LGE: I2 = 84.1, Tau2 = 0.76,
n = 647). (C) (LGE %: I2 = 0, Tau2 = 0, n = 444). (D) (ECV: I2 = 77.7, Tau2 = 0.5, n = 377).
10–15min after injection), imaging thus figure the replacement
of lost cardiomyocyte by extracellular space expansion (fibrosis),
which precludes LV decompensation and arrhythmia (39–41).
The presence of midwall fibrosis on T1-weighted imaging is
the second biomarker derivable from contrast-enhanced CMR.
Recognizing midwall fibrosis on LGE is easy and reproducible,
as only requested to differentiate from post-infarct scars that
classically involves the subendocardium, and amyloid, which
is uncommon. In this meta-analysis, there were contradictory
findings regarding the value of midwall fibrosis as a marker of
clinical outcome in AS, with overall, a moderate but significant
association between midwall fibrosis and cardiac mortality (RR:
2.88; 95%CI: 1.12–7.39). The relative amount of midwall fibrosis
similarly accounts for prognostic value, which represents another
biomarker provided by LGE. The method of quantification
of midwall fibrosis depends on patient- and contrast-specific
variables such as enhancement dynamics, CMR equipment and
the “density” of fibrosis (42). Various cutoffs to differentiate
fibrosis from the surrounding “normal” myocardium were
reported across the series analyzed, including Full Width at Mid
Height and Standard Deviations from the mean signal intensity
histogram. Although conflicting across the series (23, 36), the
percent of LGE was overall significantly associated with cardiac
mortality in AS (RR:1.05; 95%CI: 1.01–1.09). A step further,
assessing interstitial fibrosis necessitates more sophisticated
imaging approaches aiming at establishing the T1 relaxation
time mapping of the myocardium; the so-called relaxometry.
Approaches using unenhanced T1 mapping (32), post-contrast
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TABLE 3 | Rank of biomarkers according to posterior predictive p-value.
Biomarker RR 95 % CI Hedges’g 95% CrI PPPV Rank
AVC 1.19 1.05–1.36 0.08 0.01 to 0.13 0.010 2
Midwall
fibrosis
2.88 1.12–7.39 0.11 −0.34 to 0.67 0.456 4
LGE% 1.05 1.01–1.10 0.016 0.01 to 0.02 <0.0001 1
ECV 1.68 1.17–2.41 0.15 −0.06 to 0.44 0.134 3
AVC, aortic valve calcification; MF, midwall fibrosis; LGE, late gadolinium enhancement;
ECV, extracellular volume; RR, relative risk; CI, confidence interval; CrI, credible interval;
PPPV, posterior predictive p-value.
T1 mapping and a mix of both have been investigated and
validated against the extent of myocardial fibrosis on histology,
each with its own potential advantages and limitations (43). Of
these, ECV and derivatives (indexed to the body surface area)
were reported in this meta-analysis. ECV represents the volume
of distribution of the contrast agent within the myocardium,
expressed as the difference of T1 relaxation time changes after
contrast administration, corrected for the volume of distribution
by using the hematocrit. ECV also showed significant prognostic
effect in AS patients in our review (RR:1.68; 95%CI: 1.17–2.41).
Altogether place a special emphasis on the prognostic role
of CMR in AS. However, substantial inconsistency of effect
was observed for the biomarkers and the cut-offs for patient
stratification varied across the cohorts. Valve calcification for
instance is an active process independent from the skeletal
bone calcification (44), not only associated to local factors like
AS severity (15–17) or valve inflammation (45, 46), but also
distant influences in relationship with classical risk factors for
cardiovascular disease (47). As such, themechanisms of initiation
and progression of this biomarker are neither fully elucidated nor
totally predictable. This is epitomized by the fact that females
have lower AVC thanmales even after correction for body surface
area, aortic annular area and other risk factors (48), and that
severe AS with low AVC is not uncommon (49). Likewise, there is
variability on a patient basis regarding both stimuli and responses
to myocardial fibrosis. The investigations regarding myocardial
fibrosis will need similar levels of standardization as for AVC,
and a greater control for the confounders for AS-induced fibrosis
or myocardial dysfunction, such as coronary artery disease or
myocardial steatosis (50–52). Further studies will be needed
to determine the appropriate normal value ranges of above-
reported biomarkers and derivatives among subgroups by age,
sex, ethnicity, and underlying risk factors and comorbidities.
When accounting the current variability of these biomarkers for
strength of effect using network meta-analysis, midwall fibrosis,
and ECV were the weakest prognostic biomarkers (PPPV 0.456
and 0.134 respectively). This is unsurprising, as midwall fibrosis
is too prevalent to make a contributive difference among patient
groups, as being present in up to 62% of patients with severe AS
(23–25). On the other hand, ECV and its derivatives (including
unenhanced T1 values, and partition coefficient) (32, 53, 54)
that are potentially reversible and sensitive to earlier adverse
remodeling show considerable overlaps between normal and
diseased individuals (35).
The association between imaging biomarkers and patient
outcome in AS raises the question of a possible paradigm
shift in the management of AS. The efficacy of a biomarker-
based management as compared to the current approach that
relies mainly on clinical performance need to be tested by
large randomized studies. Both approaches have nevertheless
the potential to be complimentary. Considering this could help
refining the risk assessment in severe AS where patients with
good symptom/performance status and low level of relevant
imaging biomarkers being at low-risk, needing no AVR, whereas
those with altered symptom/performance status and high level
of the same imaging biomarkers requiring AVR. Consequently,
critically evaluating the benefits of AVR in intermediate-risk
groups (i.e., patients with either altered symptom/performance
status or raised imaging biomarker of poor prognosis) could be a
major research issue in the near future.
LIMITATIONS
The aim of this review was to provide an overview of imaging
biomarkers that could possibly predict clinical evolution in
patients with AS. Our search revealed only a small number
of studies, though there are other imaging biomarkers at
earlier phases of their development. Some of these newer
techniques use radiotracers (46) and others evaluate longitudinal
or circumferential myocardial dysfunction (20, 27, 28), or wall
stresses flow and deformation pattern changes (55). Our findings
link imaging biomarkers with mortality, cardiac mortality or
overall events. Nevertheless, AS-related events are often difficult
to report and subject to bias. The proportion of patients with
severe AS upon enrolment varies from 29 to 71 percent across
the series (Table 2), indicating some potentially enriched cohorts,
though the consecutive enrolment information missed in all but
two articles (23, 33). Only one study evaluated potential selection
bias via evaluation of the events that occurred >1month after
enrolment (33). Most articles did not specify the blinding of
the endpoint adjudicator(s). While AVR was often reported in
patients who did not experience symptoms, all-cause mortality,
cardiac mortality, and symptoms account for other risks than the
sole severity of AS. This was underscored in the study of Clavel
et al. where the survival after AVR was improved only in patients
with high AVC (34).
Lastly, it should be acknowledged that: first, the prognostic
value of imaging biomarkers does not necessary outperform
clinical test exploring the same pathway when available. Indeed,
the only study that evaluated the prognostic value of MPR as
a marker of microvascular dysfunction reported a significant
prediction for overall mortality (HR: 0.62; 95%CI: 0.39–0.97;
p = 0.035), which was nevertheless not superior to that of
a positive exercise testing (36). The financial burden of risk
stratification using imaging biomarkers that uses sophisticated
and costly imaging techniques could thus be reduced by
developing more cost-efficient clinical or biological biomarkers
(19, 56–59). Second, whereas the ideal biomarker for a disease
should be sensitive and consistent across age, gender and
ethnic groups, the current imaging biomarkers are imperfect
by nature, partly due to their specificity to only one of the
pathophysiological processes. Indeed, AS is a complex disease
process interplaying several pathways, placing emphasis on
multi-biomarker prognosis.
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In conclusion, AVC and myocardial fibrosis markers are
significantly associated with outcomes in AS, and have the added
potential to help the understanding of AS pathophysiology and
setting therapeutic targets.
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